Compare Ascendis Pharma A/S (ASND) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Annaly Capital Management, Inc. — how do they compare? Ascendis Pharma A/S trades at $263.79 (market cap $17.74B), while Annaly Capital Management, Inc. trades at $22.56 (market cap $16.75B). The key difference: Ascendis Pharma A/S and Annaly Capital Management, Inc. are close in size by market cap, and Annaly Capital Management, Inc. pays a 13.12% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NLY | |
|---|---|---|
Market Cap | $17.74B | $16.75B |
Sector | Health | Financials |
52-Week High | $277.18 | $24.40 |
52-Week Low | $163.32 | $19.47 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 13.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Annaly Capital Management (NLY) trades at $22.86, up 0.57% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 91.17% net income margin and 15.61% ROE, supported by a recent dividend increase to $0.75 per share. Analyst consensus is bullish with a $24.40 price target, reflecting confidence in its mortgage REIT model amid evolving Fed policy.
NLY offers a high-yield opportunity with manageable risks from interest rate sensitivity. The stock's attractive valuation (P/E 7.37, P/B 1.16) and positive cash flow trends support upside potential, though investors must monitor leverage and macroeconomic shifts that impact mortgage spreads and refinancing activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
